TNF was first described by Lloyd Old and colleagues as a protein produced in lipopolysaccharide-challenged animals and was believed to be responsible for the hemorrhagic necrosis of certain ...

Tumor necrosis factor (TNF)-alpha, a proinflammatory cytokine, has been implicated in the pathogenesis of AD. Objective: To investigate the use of a biologic TNF-alpha inhibitor, etanercept was ...

In patients with RA, TNF inhibitor use during the 3 years after being diagnosed with early-stage lung, colorectal, or prostate cancer was not linked to decreased survival.

Using vedolizumab first, before tumor necrosis factor-α inhibitors, improved quality-adjusted life-years in both ulcerative ...

TNF Pharmaceuticals (TNFA) announced that data from the Phase 2a clinical trial of its oral TNF-alpha inhibitor drug candidate isomyosamine was presented last week in a podium session at the peer ...

That research, however, was unable to confirm that anti-TNF drugs, specifically, caused the reduced risk of complications. "Previously, you could just say there was an association between early ...

SAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness of vedolizumab (Entyvio) versus ustekinumab (Stelara) and of each ...

TNF Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company that engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel ...